- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,510GBP
- Report
- September 2026
- 185 Pages
Global
From €3224EUR$3,545USD£2,771GBP
€3582EUR$3,939USD£3,079GBP
- Report
- September 2026
- 193 Pages
Global
From €3224EUR$3,545USD£2,771GBP
€3582EUR$3,939USD£3,079GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,510GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,510GBP
- Report
- August 2026
- 114 Pages
Global
From €4319EUR$4,750USD£3,713GBP
- Report
- August 2026
- 160 Pages
Global
From €3019EUR$3,320USD£2,595GBP
€3774EUR$4,150USD£3,244GBP
- Report
- July 2025
- 150 Pages
United States
From €5410EUR$5,950USD£4,651GBP
- Report
- June 2025
- 100 Pages
Global
From €5410EUR$5,950USD£4,651GBP
- Report
- January 2024
- 200 Pages
Global
From €3774EUR$4,150USD£3,244GBP
- Report
- September 2025
- 260 Pages
Global
From €4542EUR$4,995USD£3,905GBP
- Report
- October 2025
- 80 Pages
Kuwait
From €4092EUR$4,500USD£3,518GBP
- Report
- July 2022
- 40 Pages
China
From €2910EUR$3,200USD£2,502GBP

Zostavax is a vaccine used to prevent shingles, a painful and debilitating condition caused by the varicella-zoster virus. It is a live attenuated vaccine, meaning it contains a weakened form of the virus. It is approved for use in adults aged 50 and over, and is recommended for those aged 60 and over. Zostavax is administered as a single dose, and is typically given in the upper arm.
The Zostavax market is a subset of the larger vaccine market, which is estimated to be worth billions of dollars. It is a growing market, driven by the increasing prevalence of shingles and the need for effective prevention. The market is highly competitive, with several companies offering their own versions of the vaccine.
Some of the companies in the Zostavax market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and AstraZeneca. Show Less Read more